Clinical trials: Hematologic Malignancies
Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
The main aims of this 2-part study are: Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise…
- Conditions
- Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- CASSANDRA (NCT05908409)
- Testing
- IDP-121
- Where
- 11 sites in Spain
- Volunteers
- 37 people
- Sponsor
- IDP Discovery Pharma S.L.
Acute Myeloid Leukemia (AML)
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs.
- Trial name
- NCT00093600
- Testing
- cytarabine, daunorubicin hydrochloride, midostaurin
- Where
- 6 sites in United States, Germany
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL.
- Trial name
- NCT02500407
- Testing
- BTCT4465A (Mosunetuzumab) IV, Atezolizumab, BTCT4465A (Mosunetuzumab) SC
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 713 people
- Sponsor
- Genentech, Inc.
B-Cell Malignancies
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of…
- Trial name
- NCT04509700
- Testing
- Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib
- Where
- 105 sites in United States, Austria and 15 more
- Volunteers
- 112 people
- Sponsor
- Incyte Corporation
Multiple Myeloma
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate…
- Trial name
- NCT03412565
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 64 sites in United States, Brazil and 7 more
- Volunteers
- 265 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
This is an open-label, multi-dose, single-arm, Phase 1, dose-escalation study of XmAb5574. The study was conducted to identify the maximum tolerated dose (MTD) and/or recommended dose(s) (RD) for further study, to characterize…
- Trial name
- NCT01161511
- Testing
- XmAb5574
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Xencor, Inc.
Multiple Myeloma
Longterm Follow-up of Subjects Treated With bb2121
This is a multi-center, non-randomized, open label, longterm safety and efficacy follow-up study for subjects who have been treated with bb2121 in the Phase 1 clinical parent study, that evaluated the safety and efficacy of…
- Trial name
- NCT02786511
- Testing
- Safety and efficacy assessments
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Celgene
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Multicenter PK study of ASTX727 versus IV decitabine. Adult participants who were candidates to receive IV decitabine were randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m^2…
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT03306264
- Testing
- ASTX727, Dacogen
- Where
- 84 sites in United States, Austria and 8 more
- Volunteers
- 227 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Multiple Myeloma
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide…
- Trial name
- MonumenTAL-6 (NCT06208150)
- Testing
- Talquetamab, Pomalidomide, Teclistamab
- Where
- 242 sites in United States, Argentina and 25 more
- Volunteers
- 838 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myeloid Leukemia
A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory Acute Myeloid Leukemia patients.
- Trial name
- NCT07303660
- Testing
- ZE50-0134, Azacitidine Days 1-7, ZE 50-0134
- Where
- 6 sites in Russia, Uzbekistan
- Volunteers
- 66 people
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Myelogenous Leukemia
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
In this study, the efficacy and safety of nilotinib 400 mg twice daily, will be compared with imatinib 400 mg twice daily in patients with a suboptimal response to imatinib for their Philadelphia chromosome-positive (Ph+) Chronic…
- Trial name
- ENEST (NCT00519090)
- Testing
- Imatinib, Nilotinib (AMN107)
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
The purpose of the study is to determine whether CEP-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML) who achieve a second complete remission (CR).
- Trial name
- NCT00079482
- Testing
- CEP-701, high-dose cytarabine, Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)
- Where
- 81 sites in United States, Australia and 11 more
- Volunteers
- 224 people
- Sponsor
- Cephalon
Non-Hodgkin's Lymphoma, Multiple Myeloma
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
This is an open-label, single-arm, multicentre study conducted in Spain to estimate the effectiveness of palifermin administered at a dose of 60 mg/kg/day IV for 3 consecutive days before the start of the conditioning regimen and…
- Trial name
- NCT00352703
- Testing
- Kepivance (Palifermin)
- Volunteers
- 145 people
- Sponsor
- Swedish Orphan Biovitrum
Chronic Lymphocytic Leukemia
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with either FCR or BR in subjects with relapsed or refractory chronic lymphocytic leukemia.
- Trial name
- NCT00868413
- Testing
- ABT-263, FCR, BR
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Relapsed/Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
Multiple myeloma (MM) is an incurable disease characterized by the growth of monoclonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease state of etentamig in adult…
- Trial name
- NCT05286229
- Testing
- Etentamig
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- AbbVie
Cancer, Lymphoma
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
To evaluate whether palifermin (rHuKGF) administered as a single dose is non-inferior to 3 consecutive doses of palifermin in reducing the incidence of severe oral mucositis (World Health Organization [WHO] grade 3 and 4).
- Conditions
- Cancer, Lymphoma, Leukemia
- Trial name
- NCT00109031
- Testing
- palifermin, Total Body Irradiation, Cyclophosphamide
- Volunteers
- 47 people
- Sponsor
- Swedish Orphan Biovitrum
Myelodysplastic Syndrome, Myelofibrosis
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
The purpose of this study is to assess the bioequivalence of subcutaneous Vidaza® and subcutaneous Luitpold Azacitidine pharmacokinetics and to assess the comparative safety of subcutaneous Vidaza® versus subcutaneous Luitpold…
- Conditions
- Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT01290302
- Testing
- Luitpold Azacitidine, Vidaza®
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- American Regent, Inc.
Leukemia, B-cell, Lymphoma, B-Cell
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
- Trial name
- NCT04648475
- Testing
- CD19 and CD22 targeted CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
This is a multicenter prospective phase IIa dose escalation and phase IIa expansion cohort clinical trial designed to evaluate the safety and tolerability of efprezimod alfa for acute GVHD prophylaxis.
- Conditions
- Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
- Trial name
- NCT02663622
- Testing
- Efprezimod alfa, Methotrexate, Tacrolimus
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors
To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors
To observe the long-term efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory relapsed B cell hematologic tumors (at least 2 years).
- Trial name
- NCT05388695
- Testing
- Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.